Please use this identifier to cite or link to this item:
|標題:||Expression of rTS8 beta as a 5-fluorouracil resistance marker in patients with primary breast cancer||作者:||Kuo, S.J.
|關鍵字:||drug resistance;5-fluorouracil;rTS beta;nuclear localization;farnesylation;enolase;thymidylate synthase;farnesyltransferase inhibitor;thymidine kinase;messenger-rna;gene-product;rts gene;overexpression;cytotoxicity;localization;sensitivity||Project:||Oncology Reports||期刊/報告no：:||Oncology Reports, Volume 19, Issue 4, Page(s) 881-888.||摘要:||
Expression of thymidylate synthase (TS) in tumor cells is frequently suggested as an important prognostic factor for patients scheduled for chemotherapy with 5-fluorouracil (5-FU). However, clinical evidence does not fully support such an anticipation. We studied the expression of rTS beta, a reverse orientation gene of TS, as a 5-FU resistance marker in patients with primary breast cancer. Expression of rTS beta was examined in 129 patients with newly diagnosed breast cancer and five breast cancer cell lines by immunohistochemistry, immunocytochemistry and immunoblotting. Clinically, expression of rTS beta was found to correlate with survival of the patients (p=0.023) when patients received chemotherapeutic regimen containing 5-FU. In vitro, rTS beta expression was found to correlate with 5-FU resistance in breast cancer cell lines. Notably, in the 5-FU-resistant cells, rTS beta was identified in the nucleus, whereas in the 5-FU-sensitive cells, rTS beta was found in the cytoplasm. Nuclear localization of rTS beta was further found to be associated with protein farnesylation. Therefore, nuclear expression of rTS beta could be a novel 5-FU resistance marker in patients with primary breast cancer.
|Appears in Collections:||生物醫學研究所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.